6 July 2022 in Russian journal of hematology and transfusiology
Introduction. In most cases, in patients with hereditary fibrinogen deficiency, clinical manifestations are represented by bleeding of varying intensity and localization. However, the clinical picture of hereditary fibrinogen deficiency can also be represented by thrombosis.Aim — to characterize the detected mutations in fibrinogen genes and to analyze prothrombotic factors in patients with hereditary hypofibrinogenemia and thrombosis.Materials and methods. Forty-nine patients with hereditary hypofibrinogenemia were observed, of which 46 patients had no history of thrombosis and 3 patients had a confirmed history of thrombosis. These 3 patients made up the study group.Results. Heterozygous mutations were found in all 3 patients in the fibrinogen gamma chain gene (FGG), one of them had a previously undescribed deletion g.2653_2684+211del, p.(Asp167Glufs*2), which removes 32 terminal nucleotides of the fifth exon of the FGG gene and leads to the formation of a stop codon in place of amino acid 168. In two other patients, there were missense mutations c.1140T>A, p.(Cys365Ser) and c.1114A>T, p.(Asp356Val), which can determine the thrombogenic properties of the altered protein structure of fibrinogen. Other prothrombotic factors were also identified: genetic polymorphisms of low thrombotic risk, surgery, taking combined oral contraceptives.Conclusion. Hereditary fibrinogen deficiency does not play a protective role in relation to the development of thrombosis and may cause the development of thrombosis, which is associated with its multifunctional role in the hemostasis system. The pathogenesis of thrombosis in patients with hereditary hypofibrinogenemia is multifactorial and may be associated with the characteristics of the main protein defect and the coexistence of hereditary and acquired thrombotic risk factors (surgical interventions, taking combined oral contraceptives, etc.).
21 December 2025 in Russian journal of hematology and transfusiology
Introduction. The blood coagulation factor XII (FXII) is involved in opposing processes of hemostasis: contact activation of the intrinsic pathway of blood coagulation and fibrinolysis. What might the clinical picture of FXII deficiency present with: bleeding, thromboses or be asymptomatic? The issue remains debatable. Aim: To present the clinical and laboratory characteristics of patients with congenital FXII deficiency in the Russian population. Materials and methods . A retrospective study included 29 of 212 patients with FXII deficiency who underwent genetic analysis, confirming the hereditary nature of the disease. Results. The mean APTT in the study group was 187 seconds (control 29–38 sec.). The mean FXII activity was 20%. The most common mutation of F12 in the Russian population was the nucleotide substitution c.1681 –1 G>A. The reasons for contacting a hematologist and conducting diagnostics of the disease were: preoperative examination in 9 (31%) patients; abnormalities in the coagulogram during examination prior to pregnancy planning or during examination for a chronic disease in 8 (28%) patients; bleeding — in 7 (24%) patients; abnormalities in the coagulogram during screening in pregnancy in 2 (7%); family examination in 2 (7%) patients. In 21 (72%) of 29 patients, the clinical picture was represented by hemorrhagic manifestations. Thrombotic events were noted in 2 (7%) of 29 patients. Among 16 (80%) women with a history of pregnancy, miscarriages occurred in 6 (38%). Conclusion. The diagnosis of hereditary FXII deficiency is most often established during preoperative examination. However, 24% of patients consulted a hematologist with complaints of hemorrhagic manifestations, mostly mild or moderate. Surgical bleeding was noted in 21% of patients. The obstetric history of more than a third of women was complicated by miscarriages. In patients with hereditary FXII deficiency, it is necessary to be wary of mild spontaneous bleeding, surgical bleeding, miscarriage and, to a lesser extent, thromboses.
4 March 2023 in Hemoglobin
We identified a novel abnormal hemoglobin variant caused by a frameshift mutation at nucleotide position 396 in exon 3 of the β-globin gene (HBB): NM_000518:c.396delG. This variant causes an emergence of alternative amino acid sequence starting at codon 133 and a new stop codon formed in the 3' untranslated region (3'UTR) of the HBB gene at amino acid position 158. This β-globin gene variant was identified in a woman with a long history of hemolytic anemia. We named this variant Hb Ryazan after the proband's city of origin.